Butensky & Cohen Financial Security Inc. Purchases 9,277 Shares of Abbott Laboratories $ABT

Key Points

• Butensky & Cohen Financial Security Inc. increased its Abbott Laboratories stake by 26.9% in the second quarter, buying 9,277 additional shares for a total of 43,809 shares valued at approximately $3.98 million.
• Abbott reported quarterly EPS of $1.31 and revenue of $12.59 billion, beating analyst estimates, while revenue rose 13% year over year. The company guided for third-quarter 2026 EPS of $1.38–$1.46 and full-year EPS of $5.45–$5.60.
• Abbott declared a quarterly dividend of $0.63 per share, equivalent to an annualized $2.52 payout and a 2.3% yield. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $118.17.

Butensky & Cohen Financial Security Inc. raised its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 26.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 43,809 shares of the healthcare product maker's stock after buying an additional 9,277 shares during the quarter. Butensky & Cohen Financial Security Inc.'s holdings in Abbott Laboratories were worth $3,975,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories in the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter worth $26,000. Finally, Abound Financial LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at $26,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Up 1.0%

Shares of NYSE:ABT opened at $109.70 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The stock has a market cap of $189.82 billion, a price-to-earnings ratio of 35.50, a PEG ratio of 2.10 and a beta of 0.59. The business has a 50-day moving average price of $96.38 and a 200-day moving average price of $99.71.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the company earned $1.26 EPS. Abbott Laboratories's quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio is presently 81.55%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ABT. Evercore dropped their target price on Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Raymond James Financial decreased their price target on Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. Citigroup raised their price target on Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a report on Friday, July 17th. JPMorgan Chase & Co. upped their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Finally, Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.17.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source